Pancreatic Cancer Research

ResearcherUniversity of Maryland, BaltimoreActive in the last 2 years

Marco Dal Molin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1581-3576; OpenAlex author ID A5007549624. Sources: OpenAlex.

Their work

Papers
18 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: 3 papers · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 4 papers · 2026: 2 papers

Papers 18

  1. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  2. Integrated driver gene-based survival prediction in resected pancreatic cancer. Co-author DOI 10.1093/bjs/znag123↗
  3. The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Su… Co-author DOI 10.1097/sla.0000000000006794↗
  4. Editorial: To Beam, or Not to Beam-That Is the Question: Reflecting on the Role of Neoadjuvant Radiotherapy in Resectable Pancreatic Cancer. First author DOI 10.1245/s10434-025-18210-y↗
  5. ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1. First author DOI 10.7554/elife.94488↗
  6. ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 First author DOI 10.7554/elife.94488.3↗
  7. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Co-author DOI 10.1016/j.jmoldx.2020.02.010↗
  8. Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. First author DOI 10.1016/j.jmoldx.2017.09.006↗
  9. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/nature21064↗
  10. Duodenal Involvement is an Independent Prognostic Factor for Patients with Surgically Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-017-5864-9↗
  11. Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1371/journal.pone.0164195↗
  12. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Co-author DOI 10.1136/gutjnl-2014-308653↗
  13. Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Co-author DOI 10.1158/1078-0432.ccr-14-2600↗
  14. Very long-term survival in pancreatic cancer. Co-author DOI 10.18632/aging.100771↗
  15. Identification and analysis of precursors to invasive pancreatic cancer. First author DOI 10.1007/978-1-62703-287-2_1↗
  16. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Co-author DOI 10.1007/s13193-011-0073-7↗
  17. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Co-author DOI 10.1245/s10434-011-1745-9↗
  18. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Co-author DOI 10.4161/cbt.11.11.15534↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Peng He · 5 shared papers, 2017–2026 · strength 1.04
  2. Ralph H. Hruban MD · 9 shared papers, 2011–2026 · strength 0.85
  3. Michael Goggins · 9 shared papers, 2011–2026 · strength 0.62
  4. Christopher R. Shubert · 2 shared papers, 2025–2026 · strength 0.47
  5. Brady A. Campbell · 2 shared papers, 2025–2026 · strength 0.47
  6. Kelly J. Lafaro · 2 shared papers, 2025–2026 · strength 0.47
  7. Bert Vogelstein · 3 shared papers, 2015–2025 · strength 0.45
  8. Nickolas Papadopoulos · 3 shared papers, 2015–2025 · strength 0.45
  9. Kenneth W. Kinzler · 3 shared papers, 2015–2025 · strength 0.45
  10. Christopher Lee Wolfgang · 8 shared papers, 2011–2020 · strength 0.44
  11. Amanda L. Blackford · 5 shared papers, 2015–2025 · strength 0.44
  12. Linda Ye · 1 shared paper, 2025 · strength 0.42
  13. Surojit Sur · 2 shared papers, 2025 · strength 0.41
  14. Jordina Rincón-Torroella · 2 shared papers, 2025 · strength 0.41
  15. Nilofer Saba Azad · 2 shared papers, 2025 · strength 0.41
  16. Anirban Maitra · 7 shared papers, 2011–2026 · strength 0.40
  17. Laura DeLong Wood · 4 shared papers, 2015–2026 · strength 0.38
  18. Richard Andrew Burkhart · 2 shared papers, 2020–2026 · strength 0.34
  19. Zheng Li · 1 shared paper, 2026 · strength 0.26
  20. Andrea Viale · 2 shared papers, 2017–2026 · strength 0.23
  21. Alessandro Carugo · 2 shared papers, 2017–2026 · strength 0.23
  22. Huamin Wang · 2 shared papers, 2017–2026 · strength 0.23
  23. Virginia Giuliani · 2 shared papers, 2017–2026 · strength 0.23
  24. Timothy Paul Heffernan · 2 shared papers, 2017–2026 · strength 0.23
  25. Giannicola Genovese · 2 shared papers, 2017–2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.